Athlete's Foot (Tinea Pedis): Treatment and How to Prevent Recurrence

Several forms are recognised. The most common is interdigital (usually between the fourth and fifth toes): the skin is whitish, soft, flaking and cracking, itchy or burning. In the hyperkeratotic form, also called moccasin type, the skin of the sole and sides of the feet is dry, thickened and scaly, sometimes with slight redness; symptoms are mild, so it is easy to ignore. The vesicular (inflammatory) form produces small blisters and larger blisters on the sole with strong itching or pain. Lesions may occur in several forms at once and involve one or both feet.

Diagnosis on appearance alone can be unreliable, because many other conditions mimic fungal infection: eczema, foot psoriasis, contact dermatitis (for example to shoe material), dyshidrotic eczema and bacterial infections. The latest review in American Family Physician (Caplan et al., 2025) notes that clinical diagnosis without testing may be unreliable, for example tinea of the body is sometimes confused with eczema. The review by Leung et al. recommends a direct KOH preparation of skin scrapings from the active border of the lesion and, if needed, confirmation by culture or molecular methods.

Several conclusions from this review matter in practice. First, practically all classic topical drugs (allylamines such as terbinafine, azoles such as clotrimazole or miconazole, and also ciclopirox, tolnaftate and butenafine) work several times better than placebo, so the choice of a particular substance matters less than whether the drug is used correctly and for long enough. Second, allylamines have a small edge over azoles. Third, topical treatment of nails is much less effective than of skin, as we describe below.

The meta-analysis by Korting et al. confirms that terbinafine treats athlete's foot effectively even after short, one-week use once a day, with no clear advantage for longer regimens. The review by Leung et al. puts it more broadly: topical antifungal treatment is used once or twice a day for 1–6 weeks, and the prognosis with appropriate treatment is good, whereas untreated lesions may persist and progress. Azoles usually need longer use than terbinafine, so it is worth sticking to the duration given on the product leaflet.

Oral treatment is reserved for particular situations. According to reviews (Leung et al., 2023; Caplan et al., 2025) these are severe or extensive disease, failure of topical treatment, coexisting nail fungus and immune disorders. Terbinafine, itraconazole or fluconazole are used, and combining topical and oral treatment may increase the cure rate.

Oral drugs require medical consultation because they can interact with other drugs and call for risk assessment in people with liver disease. Do not reach for them on your own, all the more because in most cases topical treatment is enough. The review by Caplan et al. adds that newer, more severe infections with dermatophytes that do not respond to first-line treatment are emerging; they need prolonged oral treatment and specialised testing, which is another reason to see a doctor if there is no improvement after a correctly conducted course.

Recurrences usually have several causes, often overlapping. The first is stopping treatment too early: itching and scaling go away faster than the fungus is eliminated, so stopping after a few days leads to return of the lesions. The second is untreated nail fungus. The Cochrane review on oral treatment notes that infection can spread to the nails, which become a source of reinfection of the skin. The third is the environment: damp shoes and socks, shared towels and mats, wet floors in swimming pools, saunas and gyms, and household members with untreated fungal infection. The fourth is predisposing factors: sweaty feet, circulation disorders, diabetes and reduced immunity.

The review by Nowicka and Nawrot (Mycoses, 2021), written by a team from Wrocław, draws attention to the role of podiatric management, that is, foot care, in the spread, prevention and treatment of fungal infections, and to counselling on long-term prevention. Well-designed randomised trials assessing individual hygiene recommendations are few, so the recommendations below rest on the mechanism of infection and clinical practice rather than hard data.

Nails are a much harder target than skin: the drug has to penetrate the nail plate, and the infection is treated for months. The Cochrane review on topical treatment (Crawford and Hollis, 2007) states that ciclopiroxolamine and butenafine may be effective but must be applied daily for a long time (at least a year), and in six nail trials ciclopiroxolamine had poor cure rates, whereas amorolfine might be much more effective. According to the review by Caplan et al., oral terbinafine is considered first-line treatment for nail fungus because it is well tolerated, effective and inexpensive.

In practice this means that if foot-skin fungus keeps returning despite correct treatment and the nails are changed, it is worth testing and possibly treating the nails as well, because otherwise the risk of recurrence remains. Diagnosis should be confirmed by mycological testing, since thickened, brittle nails may also result from repeated minor trauma or psoriasis. Details of nail fungus treatment are beyond the scope of this article.

In people with diabetes a fungal skin lesion of the foot is more than a cosmetic problem, because cracks in the skin between the toes can be a portal of entry for bacteria. The review by Bristow and Spruce (Diabet Med, 2009), covering 16 studies, indicates that there is some evidence that fungal foot infection is a factor in the development of cellulitis of the lower limb, particularly when the infection is located between the toes. At the same time the authors stress that most studies diagnosed fungal infection clinically rather than microbiologically, and that there were too few data to say that fungal foot infection clearly increases risk in patients with diabetes.

The practical conclusions are consistent, however: people with diabetes, circulation disorders, neuropathy or reduced immunity should inspect their feet daily (including between the toes), report cracks, redness or oozing, and treat fungal infection early under medical supervision, without long experimentation with home remedies. Oral antifungals call for particular caution in them because of drugs taken chronically. We cover the diabetic foot in separate texts, and diabetes itself in our knowledge base.

It is similarly wise to be cautious about 'miracle' home remedies such as soaking the feet in vinegar, baking soda or tea tree oil. The reviews we draw on contain no data confirming their efficacy compared with drugs, and delaying proper treatment lets the infection persist and spread to others and to the nails. Pharmacy preparations with terbinafine are available without a prescription and have the best evidence.

Athlete's foot is well understood and usually easy to cure if the diagnosis is right and treatment is consistent. The biggest gain comes from confirming the diagnosis, choosing a topical drug with documented efficacy (terbinafine or an azole), not stopping the course when itching goes, and making sure feet, shoes and nails stop being sources of reinfection. People with diabetes and reduced immunity should not delay seeing a doctor.